Physostigmine treatment of gamma-hydroxybutyric acid overdose: appropriate or inappropriate use of a reversal agent?
Mullins
M E
ME
Dribben
W
W
D000777:Anesthetics / Q000008:administration & dosage / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced* / Q000517:prevention & control; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D062787:Drug Overdose / Q000188:drug therapy; D006801:Humans; D006885:Hydroxybutyrates / Q000008:administration & dosage / Q000009:adverse effects*; D009388:Neostigmine / Q000009:adverse effects; D010830:Physostigmine / Q000009:adverse effects* / Q000627:therapeutic use
D000777:Anesthetics; D002800:Cholinesterase Inhibitors; D006885:Hydroxybutyrates; C111420:4-hydroxybutyric acid; D009388:Neostigmine; D010830:Physostigmine